Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Pinealon, Tripeptide bioregulator
A short chain tripeptide bioregulator (Glu-Asp-Arg) from the Khavinson program, studied for neuroprotection and a proposed, but under validated, direct gene promoter binding mechanism.

An ultrashort tripeptide bioregulator studied for protecting neurons, with a striking, under validated claim that it binds DNA directly to tune gene expression.
Oxidative stress reduction
Memory support
Marketed claim
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Marketed for neuroprotection, cognition, and circadian/sleep support. Carries the same single network limitation as Epitalon and BPC-157, essentially all evidence is from Khavinson's group. PubMed returns no completed peer reviewed RCTs; a Russian observational TBI study and rodent learning data exist. The DNA promoter binding mechanism is the most cited and least clinically validated part of the story.
No significant adverse effects in the thin (mostly preclinical/Russian) literature, but human safety is effectively uncharacterized, no PK, toxicology, or long term data. Theoretical concern of unknown off target gene effects.
Pregnancy; active malignancy (theoretical); anyone unable to verify product quality.
Not FDA approved; research use only / gray market. Often paired commercially with Epitalon as a 'Russian longevity stack.' WADA: S0.
Subcutaneous or intranasal, short courses. Oral bioavailability is very poor.
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.